A phase III study of patients with allergic asthma (defined as elevated serum IgE in the presence of at least one positive allergen-specific skin prick test) on medium-to-high-dose ICS showed a nearly 50% reduction in asthma exacerbations compared to placebo (0.28 exacerbations per patient over the 16-week steroid stable phase in the omalizumab group versus 0.54 in controls, p = 0.006) coupled with an ability to reduce ICS doses but few other clinical improvements (33). This evidence concerns the gene IGHE and asthma.